Antibiotic addition to further replenish pipeline
Basilea Pharmaceutica has announced a preclinical antibiotic programme asset purchase agreement, aligning with management’s pre-emptive...
top of page
Adam Strydom
Jan 241 min read
Growth Pivot with Potential Antibacterial Addition
Basilea Pharmaceutica has announced an exclusive evaluation licence and option agreement with South Korea-based iNtRON Biotechnology...
10
Adam Strydom
Jan 221 min read
FDA Accepts New Drug Application for Ceftobiprole
Basilea Pharmaceutica has announced that the US FDA has accepted its New Drug Application (NDA) for ceftobiprole. The FDA has set a...
20
Adam Strydom
Jan 191 min read
Differentiating Immunotherapy Truths vs Opinion
Personalised treatment continues to be a major theme observed at the annual American Society of Clinical Oncology (ASCO) meeting, much...
10
Adam Strydom
Jan 191 min read
Prompt Receipt of Milestone Payments for Cresemba
Basilea Pharmaceutica has announced receipt of two separate sales-related milestone payments totalling US$26.25m (CHF23.7m) from...
10
Adam Strydom
Jan 181 min read
Zevtera NDA Submission Pushed to Q323
Basilea Pharmaceutica has announced that there will be a minor delay in the timing of its new drug application (NDA) for Zevtera...
10
Adam Strydom
Jan 181 min read
Solid FY22 Marked by Broad-Based Growth
ERGOMED, a services business which includes an industry-leading suite of specialist pharmacovigilance solutions, reported FY22 results...
20
Adam Strydom
Jan 181 min read
Cresemba Expansion Continues with Japan Launch
Basilea Pharmaceutica has announced that it has received a development-related milestone payment of CHF5m from its Japanese licensing...
20
Adam Strydom
Jan 181 min read
Strong Execution Resulting in Operating Profitability
On the heels of management’s January upward guidance revision, continued strong execution of Basilea Pharmaceutica’s outlined strategic...
10
Adam Strydom
Jan 181 min read
Cresemba Milestone Payment Triggered
Basilea Pharmaceutica has announced that it has received a sales-related milestone payment of CHF20m from its US licensing partner...
10
Adam Strydom
Jan 181 min read
Third Leg of Strategy Executed With Debt Repayment
Basilea Pharmaceutica is focused on treating infectious diseases. Basilea has announced the full repayment of the CHF113.8m outstanding...
10
All
bottom of page